BioNTech
Founded Year
2008Stage
PIPE | IPOTotal Raised
$771.5MMarket Cap
30.05BStock Price
132.44Research containing BioNTech
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned BioNTech in 4 CB Insights research briefs, most recently on Apr 19, 2021.
Expert Collections containing BioNTech
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
BioNTech is included in 3 Expert Collections, including Cancer.
Cancer
4,784 items
Pharmaceutical and biotechnology companies with cancer therapy drug candidates.
Regenerative Medicine
1,818 items
Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).
Biopharma Tech
15,535 items
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
BioNTech Patents
BioNTech has filed 166 patents.
The 3 most popular patent topics include:
- Clusters of differentiation
- Immunology
- Immune system
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
6/18/2019 | 5/31/2022 | Immune system, Immunology, Clusters of differentiation, Transcription factors, Proteins | Grant |
Application Date | 6/18/2019 |
|---|---|
Grant Date | 5/31/2022 |
Title | |
Related Topics | Immune system, Immunology, Clusters of differentiation, Transcription factors, Proteins |
Status | Grant |
Latest BioNTech News
Jun 24, 2022
Paul Kagame, president of Rwanda (center L) and Ugur Sahin CEO of BioNtech (R) mark the beginning of the construction of a mRNA vaccine factory, Kigali, 23 June 2022. - Copyright © africanews Rwandan president Paul Kagame and BioNtech's CEO Ugur Sahin launched on Thursday, the construction of a messenger RNA vaccine factory in Kigali. It is Africa's first of three planned projects on the continent and aims to produce treatments against Covid-19 and other diseases by early 2024. "BioNTech is researching and developing vaccines and medicines to prevent malaria, tuberculosis and HIV. These deseases are major causes of mortality on the African continent. We've partnerd with the Bill and Melinda Gates Foundation to develop the tuberculosis and HIV vaccines and we are developing malaria vaccines. ", said Ugur Sahin, BioNTech's CEO. Paul Kagama called the project "grounbreaking" and said his country worked to attract biopharmaceutical researchers in the manufacturing sector. Production will include vaccines against Covid, but also pioneering treatments currently in development against malaria, tuberculosis and HIV, diseases that are ravaging Africa. Human trials of a BioNTech malaria vaccine using mRNA technology are expected to begin in late 2022. Africa is the world's least vaccinated continent against Covid-19. Less than 20% of its 1.2 billion population have received two doses of vaccine. Related articles
BioNTech Web Traffic
BioNTech Rank
When was BioNTech founded?
BioNTech was founded in 2008.
Where is BioNTech's headquarters?
BioNTech's headquarters is located at An der Goldgrube 12, Mainz.
What is BioNTech's latest funding round?
BioNTech's latest funding round is PIPE.
How much did BioNTech raise?
BioNTech raised a total of $771.5M.
Who are the investors of BioNTech?
Investors of BioNTech include Temasek, Bill & Melinda Gates Foundation, Sanofi, Pfizer, Invus Group and 8 more.
Who are BioNTech's competitors?
Competitors of BioNTech include HDT Bio.
You May Also Like
HDT Bio is a biopharmaceutical company formed to address critical unmet needs to treat cancers and infectious diseases. It is based in Seattle, Washington.
Moderna Therapeutics (NASDAQ:MRNA) is a Cambridge, Massachusetts-based biotechnology company that is focused on drug discovery and drug development based on messenger RNA. The company creates synthetic mRNA that can be injected into patients to help them create their own therapies.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.